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Summary Thirty-eight patients with previously treated Hodgkin's disease were given high dose combination
chemotherapy using melphalan and BCNU and autologous bone marrow transplantation. In 25 patients
etoposide was added in conventional dosage. During the course of the study the dose of melphalan was
increased from 80 to 140mgm-2 and the dose of BCNU from 300 to 600mgm-2. The response rate was
76% with 53% complete remission. Forty-five per cent of the patients are free of disease at 4-20 months
follow-up. There were eight (26%) treatment-related deaths due to lung damage (seven cases) and irreversible
cardiac failure (one case). Fatal lung damage occurred only in patients receiving 600 mgm 2 of BCNU with
high dose melphalan. The dose of BCNU given with high dose melphalan should not exceed 500mgm2.
This treatment is effective against relapsed Hodgkin's disease but must be used cautiously. The best time for
its use remains to be determined.
Despite improvements in radiotherapy and chemotherapy
during the past 30 years, approximately 30% of patients
with Hodgkin's disease (HD) will still die of their disease
(Selby & McElwain, 1987). Relapse after chemotherapy or
failure to achieve remission with the first line treatment are
ominous. Second line combination chemotherapy can
produce good remission rates but cures are uncommon
(Taylor et al., 1982; McElwain et al., 1985; Santoro et al.,
1986; Hagemeister et al., 1987). Radiotherapy can
occasionally produce remissions in patients relapsing from
chemotherapy (Roach et al., 1987; Fox et al., 1987).
High dose chemotherapy with autologous bone marrow
transplantation (ABMT) has been explored in the treatment
of relapsed or resistant HD (Canellos, 1985; Canellos et al.,
1987). Recent reports indicate a high response rate between
52 and 95% with 18-70% relapse-free survival at 1-66
months (Ahmed et al., 1987; Carella et al., 1987; Jagannath
et al., 1987; O'Reilly et al., 1987; Philip et al., 1986). We
initially explored high dose chemotherapy for HD with
melphalan, 200 mgm2, followed by ABMT (Russell et al.,
1988). This produced a high response rate without treatment-
related deaths and a 20% relapse-free survival at 5 years. It
seemed probable that the results might be improved by a
combination of active drugs given at high dose with ABMT.
Among them, BCNU and etoposide are widely used. Thus,
in the present study these drugs have been added to
melphalan to make the combination known as MBE.
Patients and methods
Chemotherapy regimen
For purposes of description, day 0 is the day when the
autologous bone marrow is returned to the patient. MBE
consisted of BCNU given intravenously on day -5 as a
slow intravenous push over 10min, melphalan given
intravenously on day -4 with forced hydration as reported
elsewhere (McElwain & Powles, 1983) and etoposide given
intravenously on days -5, -4 and -3.
Dose escalation
The first two patients received BCNU 300mgm-2, etoposide
1,200mgm 2 and melphalan 80mgm-2 (one patient) or
melphalan 100mgm-2 (one patient). Both developed severe
Correspondence: T.J. McElwain.
mucositis and the dose of etoposide was thereafter reduced
to 300mgm 2. The remaining 36 patients received
melphalan 140 mgm-2 and the dose of BCNU was
increased. One of these patients received BCNU 300mgm-2;
11 received 400mgm 2; three received 500mgm-2 and 21
received 600mgm-2. Twenty-three patients received
etoposide 300mgm-2. Thirteen patients were not given any
etoposide because their tumours had been previously shown
to be refractory to this drug in this dose. Therefore 25
patients had a three drug combination with melphalan,
BCNU and etoposide and 13 patients had a two drug
combination with melphalan and BCNU only. Table II
shows graphically the level of dosage and the drugs given in
different groups of patients.
Patients
From November 1985 until November 1987, 38 consecutive
patients with HD received MBE with ABMT. Twenty-three
were male and 15 female. Ages were between 15 and 51 with
a median of 28. Twenty-four patients had nodular sclerosing
histology, six mixed cellularity, five lymphocyte depletion,
one lymphocyte predominance and two were unclassified.
Before high dose treatment, patients were assessed by full
blood count, erythrocyte sedimentation rate, urea, creatinine,
liver function tests, glomerular filtration rate, bone marrow
aspirate and trephine, chest X-ray and CT scan of chest and
abdomen. Lung function and cardiac ejection fraction was
not routinely measured.
Ann Arbor stages at initial diagnosis were IA for two
patients, IIA for four, IIB for three, IIIA for two, IIIB for
nine, IVA for five and IVB for 13. Eight patients had never
achieved a complete remission and were considered to have
primary drug resistant disease (Table I). Ten patients
received MBE as a consolidation therapy when in complete
remission achieved only after multiple previous combination
drug treatments (Table I). The 20 remaining patients had
relapsed from previous complete remissions. None of the
prior complete remissions had lasted longer than 2 years.
Sixteen of them had received drug combinations for their
relapses but failed to enter complete remission before
receiving MBE. Four had received such treatments but failed
to respond (Table I).
All patients referred to the Academic Medical Unit with
relapsed or resistant HD were considered for this treatment.
However, patients were excluded if they were unfit (WHO
performance status <2; renal, hepatic or marrow failure) age
>60 years or if their disease was very advanced and had
been completely refractory to more than two combinations
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Table I Details of patients
Sex, age Previous Response MBE duration Survival Cause of
initial stage therapy at 3 months (months) Status (months) death
Patients with resistant disease who never achieved CR before receiving MBE
1. F, 18, IVB
2. F, 30, IIB
3. M, 29, IVB
4. F, 19, IIIB
5. M, 50, IVB
6. F, 29, IIIB
7. F, 32, IVB
8. M, 41, IVB
a, k
a, k
C,j, O
b, j, k
b, j, o
a, g
a, k
k
NE
NE
CR
NE
CR
PR
PR
CR
Patients who received MBE in complete remission
9. M, 29, IA RT, a, g CR
10. F, 27, IVA a, i, RT, g CR
11. F, 21, IVA a, RT, g CR
12. M, 28, IIA d, e, RT, g CR
13. M, 29, IIIB c, a, 1 CR
14. M, 23, IIB c, b, RT, k CR
15. M, 20, IVB a, k CR
16. F, 19, IVB c, n, l PD
17. F, 33, IVB c, j NE
18. M, 19, IVA f, a NE
Patients relapsing from previous CR given MBE with measurable disease
19. M, 42, IIA
20. M, 31, IIIB
21. M, 28, IIA
22. F, 21, IVA
23. M, 16, IVB
24. M, 24, IIA
25. F, 41, IA
26. M, 19, IIIA
27. M, 36, IIIB
28. M, 51, IVB
29. F, 22, IVA
30. M, 26, IIIB
31. F, 31, IIIB
32. M, 41, IIIB
33. M, 38, IVB
34. M, 17, IIB
35. F, 48, IVB
36. M, 15, IVB
37. F, 28, IIIA
38. M, 22, IIIB
RT, a, o, m
a, b, g, RT
c, RT, a, 1
a, RT, g
a, o
a, h, j
RT, a, 1, HP
a, RT, g
a, g
a, 1, k
a, g, RT
a, j, k
a, n, g, k
c, a, 1
a, g, k
a, RT, k
j, a, HDM
a, k
a, k
a, g
PR
PR
PR
CR
PR
NC
CR
CR
PR
CR
CR
CR
NE
PR
PR
NC
CR
CR
CR
CR
a=ChlVPP,ChlOPP,LOPP=chlorambucil-vinblastineor vincristine-procarbazine-prednisolone.
b=COPP,COMP,CVPP=cyclophosphamide-vincristine or vinblastine-procarbazineor methotrexate-
prednisolone.
c=MOPP,MVPP=mechloretamine-vincristine or vinblastine-procarbazine-prednisolone.
d=C-MOPP=cyclophosphamide-MOPP.
e=CHOP=cyclophosphamide-adriamycin-vincristine-prednisolone.
f=MBACOD =methotrexate-bleomycine-adriamycin-cyclophosphamide-vincristine-dexamethasone.
g =HOPE-B,BEVAP =adriamycin-vincristine or vinblastine-prednisolone-etoposide-bleomycine.
h=OPEC=vincristine-prednisolone-etoposide-chlorambucil.
i=PABLOE=prednisolone-adriamycin-bleomycine-chlorambucil-vincristine-etoposide.
j =ABVD,ABVVP16,ADVVP16 =adriamycin-bleomycine or dacarbazine-vinblastine-dacarbazine or
etoposide.
k=VEEP=vincristine-epirubicin-etoposide-prednisolone.
I=EVAP=etoposide-vinblastine-adriamycin-prednisolone.
m=VEC=vincristine-epirubicin-cyclophosphamide.
n =VBC,CVB =vinblastine-BCNU-cyclophosphamide.
HDM=high dose melphalan.
HP=high dose methylprednisolone.
o =others.
RT=mantle, para-aortic, inverted Y or involved fields radiotherapy.
CR=complete remission, PR=partial remission, NC=no change, PD=progressive disease, NE=not
evaluable, + =continuing.
of drugs. Eligible patients were informed of the nature of the
treatment and in particular the present level of knowledge
about high dose chemotherapy
- its efficacy and risks - was
made clear together with alternative treatments when
available. Only those who consented received MBE with
ABMT.
Previous treatments
Twenty-eight patients had measurable disease at the time of
treatment with MBE. Twelve were resistant to conventional
dose chemotherapy (eight with primary resistant disease and
four with resistant relapses). Thirty-seven patients had
already received an alkylating agent and procarbazine based
regimen and 27 of them had also received a second line
treatment with adriamycin containing regimens. Thirty-three
had received prior etoposide, 23 bleomycin and 13 previous
radiotherapy (Table I). Eighteen of these patients were given
elective treatment with combination chemotherapy in
conventional dosage for relapse until they achieved
maximum response with the intention of proceeding then to
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high dose chemotherapy and an autologous bone marrow
transplant. These regimens were vincristine-epirubicin-
etoposide-prednisolone (VEEP) for 12 patients, adriamycin-
vincristine-prednisone-etoposide-bleomycin (HOPE-B) for
three, ChlVPP for two and high-dose methylprednisolone for
one.
Bone marrow
In all cases bone marrow aspirates and trephines were clear
of HD at the time of harvest. Harvests were obtained under
general anaesthetic from anterior and posterior iliac crests
and from the sternum. The marrow was centrifuged and its
buffy coat diluted into normal saline at a final concentration
of 5% DMSO and then cryopreserved. In 16 patients the
marrow was harvested before the conventional drug
treatment. Two patients had two harvests to obtain adequate
cell numbers, the minimum required being 1.5 x 108
nucleated cells per kilogram body weight. No purging or
other in vitro manipulation of the marrow was attempted.
Marrow was returned at least 2 days after the last drug
administration and the day of marrow return is designated
day 0.
Nursing care
Patients were nursed in side rooms of general medical wards
without special isolation procedures. They received oral
antifungal prophylaxis with nystatin suspension and
amphotericin lozenges. Toxicity was evaluated daily and
assessed on the WHO scale (WHO, 1979). A triple antibiotic
combination with gentamycin 80mg 8-hourly, piperacillin 4g
6-hourly and flucloxacillin 500mg 6-hourly was started on
day 1 and continued until the total white cell count
recovered to 1 x 109 1-1 with at least 40% neutrophils.
Appropriate changes in antibiotic treatment were made
according to the clinical course. Antiviral chemotherapy
prophylaxis was not routinely used.
Definition of response
Complete remission was defined as the disappearance of all
abnormalities related to Hodgkin's disease and partial
remission as 50% reduction in measurable tumour volume
with associated symptomatic improvement. Early death was
defined as any death occurring within 3 months after
treatment regarded as being treatment related. Late toxic
death is any treatment-related death occurring after 3
months. Patients who died early were not scored as
responders even if tumour regression had occurred. Response
rates were calculated as a proportion of all patients. An
autopsy was performed in all but one patient who suffered
toxic death.
Results
Therapeutic effect (responses assessed at 3 months)
Among 28 patients who had measurable disease there were
13 complete remissions (CR=46%), nine partial remissions
(PR=32%) and two did not respond (NR=7%). Four died
early within 3 months (ED= 14%). Among the 10 patients in
CR when treated, seven (70%) remained in CR at 3 months,
two had ED (20%) and one progressed within 3 months. At
the 3 months follow-up point, the overall outcome was 20
CR, 9 PR, 2 NR, 1 PD and 6 ED (Tables I and III).
One patient (patient 7, Table I) entered PR after MBE
and is reported as such in Table I, Figure 2 and Figure 3.
She received mantle irradiation to her residual disease
(mediastinum and neck) which resulted in a CR which
continues at 14 months.
Forty-five per cent of the patients assessable for response
at 3 months are alive and in complete remission with a
follow-up from 4 to 20 months (median 12 months). The
overall cumulative probability of survival is 31% at 2 years
(Figure 1). However, the actuarial probability of remaining
in remission for the 20 patients in CR at 3 months is 86% at
2 years. It is only 19% at 1 year for nine patients achieving
a PR (Figure 2). The probability of disease free survival for
patients in CR after MBE is 70% at 2 years as a
consequence of late toxic deaths (Figure 3).
Table II Chemotherapy regimen and dose escalation
(numbers of patients)
BCNU (mgm-2)
Melphalan Etoposide
(mgm-2) 300 400 500 600 (mgm-2)
80 1 1,200
100 1 1,200
140 1 11 1 10 300
140 2 11 0
Table III Response to MBE
No. CR(%) PR(%) NR(%) ED(%)
Patients
never in CR 8 3 2 3
Patients
in CR 10 7 1 2
Patients
relapsing 20 10 7 2 1
Overall 38 20 (53) 9 (24) 3 (8) 6 (16)
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Figure 1 Overall probability of survival for 38 patients treated
with MBE.
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Figure 2 Probability of remaining in remission for 20 patients
in CR after MBE ( ) and 9 patients in PR (-). The patient
who remains in remission after entering PR on MBE received
mantle radiotherapy to her residual disease which led to a CR.
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Figure 3 Probability of disease-free survival for 20 patients in
CR after MBE ( ) and 9 patients in PR (---). The patient
who remains in remission after entering PR on MBE received
mantle radiotherapy to her residual disease, which led to a CR.
Bone marrow transplant
Cryopreserved bone marrow was returned on day 0
according to standard procedures, patients receiving a
median of 2.1 x 108 (range 1.42-6.0 x 108) frozen nucleated
cells per kilogram of body weight. Median time to recover
1 x 1091-1 leucocytes was 25 days (range 9-115) and all
patients achieved a satisfactory white cell graft. Median time
to recover 50 x 1091- 1 platelets was 51 days (range 17-314+)
but four patients failed to reach this limit after 168, 253, 302
and 314 days. A level of 50 x 109 1-1 platelets was reached as
late as day 137 in one patient.
Toxicity
Acute toxicity included transient gastrointestinal side effects
with nausea, vomiting, mucositis and diarrhoea. (See Table
IV.) Clinical evidence of infections was common during the
agranulocytic phase and required changes in wide spectrum
antibiotics in 32 patients (84%). Transient renal toxicity
measured by the serum creatinine level occurred in nine
patients (24%). Transient changes in the liver function tests
were noticed in 18 patients (47%) without clinical evidence
of liver disease. Fatal cardiac toxicity occurred in one patient
who died on day 26 of biventricular failure (patient 4, Table
I). This patient had previously received extensive
anthracycline therapy but autopsy did not reveal any
evidence of specific drug-induced cardiac abnormalities.
The most severe toxicity of MBE was respiratory failure.
There were seven toxic deaths from this cause, five occurring
before 4 months and two late deaths. The five early deaths
due to respiratory failure occurred on days 19, 58, 66, 78
and 103 and all of these five patients had received BCNU
600mgm-2. Three of them had received previous bleomycin.
The clinical course was acute pneumonitis leading to adult
respiratory distress syndrome and autopsy showed interstitial
pneumonitis compatible with drug-induced damage and no
residual HD. The clinical pattern in the two patients with
late respiratory failure was quite different. One patient who
previously had chronic respiratory insufficiency probably
Table IV MBE toxicity according to WHO
scale
1 2 3 4
Gastrointestinal 8 16 10 3
Infections 4 11 16 1
Renal 4 3 1 1
Hepatic 7 6 4 1
Pulmonary 1 4 1 5
Cardiac 0 0 0 1
related to bleomycin died on day 255 with respiratory failure
of gradual onset (patient 3, Table I). He had received BCNU
300mgm 2. No HD was found at autopsy and the lungs
were fibrotic. Another patient (patient 29, Table I) died of
respiratory failure on day 424. She had developed chronic
pleural thickening with small lungs. A thoracotomy showed
the lungs to be fibrotic but with no evidence of recurrent
Hodgkin's disease. The pleura were resected but she died in
the postoperative phase. Five additional patients had
transient breathlessness with radiological evidence of
pneumonitis following MBE but recovered fully. Among
these five patients, two had received BCNU 600 mgm-2, one
500mgm-2 and two 400mgm-2. All patients with lung
toxicity were treated with high dose steroids. Five (24%) of
the 21 patients treated with 600mgm2 of BCNU died of
early lung toxicity and two more had transient respiratory
symptoms. Of the 17 patients treated with less than
600mgm2 of BCNU, none has died of early lung toxicity
but four (24%) had non-fatal lung damage. The death rate is
significantly different between patients who received
600mgm- 2 of BCNU and those who received lower doses
of BCNU (Fisher's exact probability=0.04). The association
between the dose of BCNU and the subsequent lung toxicity
is very strong. We have analysed other possible contributory
factors including previous chemotherapy and previous
radiotherapy and we cannot demonstrate evidence
implicating them in the lung damage. In particular, only one
of the patients who died of heart or lung toxicity had ever
received thoracic irradiation.
Discussion
This analysis allows us to draw some conclusions about the
use of melphalan and BCNU in high dose in combination
for Hodgkin's disease and in particular to highlight our
substantial concern about their toxicity to the lungs.
BCNU in high dose as a single agent is toxic to the lung
but such toxicity is rare with doses below 800mgm-2 (Perren
et al., 1987). Melphalan alone causes transient, clinically
insignificant lung toxicity (Allen et al., 1986). High dose
melphalan, 200mgm 2, did not produce significant lung
toxicity during a prior study in a comparable group of
patients (Russell et al., 1988). With combination of doses of
melphalan 140mgm 2 and BCNU 600mgm-2 we have seen
a high rate of toxic deaths due to lung damage. This must
represent an additive toxic effect and this incidence of severe
toxicity precludes their usage together at these doses in these
patients. The use of another alkylating agent,
cyclophosphamide, given at high dose in combination with
high dose BCNU and etoposide was not reported to cause
such a high lung toxicity (Ahmed et al., 1987; Carella et al.,
1987; Jagannath et al., 1987; O'Reilly et al., 1987; Philip et
al., 1986). In combination with high dose melphalan,
140mgm2, we now limit the dose of BCNU to a maximum
of 500mgm2.
Nevertheless, there is no doubt that this approach leads to
high remission rate for patients with very aggressive HD. In
our study the overall response rate to MBE was 76%, with
53% of patients in CR at 3 months. The actuarial risk of
relapse before 2 years is only 14% but median follow-up is
only 1 year. The overall survival falls to 31% at 2 years as a
consequence of the toxic deaths. Since the goal of these
treatments is long-term disease-free survival, follow-up to 5
years is required to allow firm conclusions. The precise place
of intensive chemotherapy for HD remains to be determined.
To date all studies including this one have suffered from case
selection and lack of a control arm. Studies are now required
in relapsed or resistant patients to randomise conventional
treatment against intensive regimens. Intensive treatments
are likely to be associated with far less toxicity than hitherto,
both because of what has been learned from studies of the
type reported here and the relative lack of prior tissue
damage in patients who receive high dose treatment earlier.HIGH DOSE CHEMOTHERAPY FOR HODGKIN'S DISEASE 635
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